Ira Pastan Selected Research

immunotoxin HA22

11/2021	Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia.
1/2021	Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.
1/2020	Immunogenicity of Immunotoxins Containing Pseudomonas Exotoxin A: Causes, Consequences, and Mitigation.
1/2020	Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia.
1/2020	Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia.
10/2018	Recombinant immunotoxins with albumin-binding domains have long half-lives and high antitumor activity.
1/2018	Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up.
1/2018	Interactions Between Pseudomonas Immunotoxins and the Plasma Membrane: Implications for CAT-8015 Immunotoxin Therapy.
1/2018	5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox.
1/2018	Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ira Pastan Research Topics

Disease

180	Neoplasms (Cancer) 01/2022 - 03/2001
41	Mesothelioma 01/2022 - 06/2002
38	Hairy Cell Leukemia 11/2021 - 02/2002
19	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 05/2005
16	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 05/2002
15	Prostatic Neoplasms (Prostate Cancer) 12/2018 - 03/2002
15	Leukemia 10/2018 - 04/2002
14	Breast Neoplasms (Breast Cancer) 01/2022 - 05/2002
13	Malignant Mesothelioma 03/2020 - 06/2004
13	Adenocarcinoma 03/2020 - 08/2003
13	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2020 - 03/2010
12	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 04/2014 - 02/2002
11	Hematologic Neoplasms (Hematological Malignancy) 01/2020 - 10/2006
10	Neoplasm Metastasis (Metastasis) 03/2020 - 02/2002
8	Lung Neoplasms (Lung Cancer) 11/2020 - 06/2002
8	Adenocarcinoma of Lung 01/2020 - 06/2002
8	Glioma (Gliomas) 01/2016 - 01/2005
8	Glioblastoma (Glioblastoma Multiforme) 01/2016 - 05/2002
7	Proteinuria 01/2019 - 04/2005
7	Lymphoma (Lymphomas) 04/2013 - 07/2002
6	Hemolytic-Uremic Syndrome 10/2017 - 09/2005
6	Carcinoma (Carcinomatosis) 04/2017 - 10/2006
6	Testicular Neoplasms (Testicular Cancer) 01/2012 - 03/2002
5	Capillary Leak Syndrome 11/2020 - 01/2013
4	Fibrosis (Cirrhosis) 01/2021 - 01/2016
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2020 - 06/2002
4	Residual Neoplasm 01/2020 - 05/2006
4	Edema (Dropsy) 01/2019 - 04/2005
4	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 05/2017 - 01/2010
4	Stomach Neoplasms (Stomach Cancer) 04/2016 - 02/2002
4	Disease Progression 12/2014 - 06/2010
4	Non-Hodgkin Lymphoma (Lymphosarcoma) 02/2014 - 10/2006
4	B-Cell Lymphoma (Lymphoma, B Cell) 05/2012 - 11/2006
4	Brain Neoplasms (Brain Tumor) 01/2012 - 10/2003
3	Inflammation (Inflammations) 01/2022 - 01/2019
3	Colorectal Neoplasms (Colorectal Cancer) 03/2020 - 12/2007
3	Hepatocellular Carcinoma (Hepatoma) 01/2020 - 05/2008
3	Hypersensitivity (Allergy) 01/2019 - 12/2014
3	Hypoalbuminemia 10/2017 - 09/2005
3	Thrombotic Microangiopathies 10/2017 - 09/2014
3	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2017 - 09/2007

Drug/Important Bio-Agent (IBA)

137	Immunotoxins (Immunotoxin)IBA 01/2022 - 02/2002
80	MesothelinIBA 01/2022 - 06/2002
64	Proteins (Proteins, Gene)FDA Link 01/2022 - 02/2002
38	AntigensIBA 12/2018 - 03/2001
32	ExotoxinsIBA 01/2020 - 04/2002
29	Monoclonal AntibodiesIBA 03/2020 - 03/2001
19	Pharmaceutical PreparationsIBA 01/2020 - 03/2001
19	AntibodiesIBA 12/2018 - 04/2002
18	immunotoxin HA22IBA 11/2021 - 11/2006
16	LMB-100IBA 11/2020 - 08/2014
12	Differentiation AntigensIBA 01/2021 - 06/2004
11	Membrane Proteins (Integral Membrane Proteins)IBA 12/2020 - 02/2003
11	Messenger RNA (mRNA)IBA 01/2016 - 03/2002
10	EpitopesIBA 01/2022 - 04/2004
10	Surface Antigens (Surface Antigen)IBA 11/2020 - 04/2004
10	Peptides (Polypeptides)IBA 12/2018 - 04/2004
9	amatuximabIBA 12/2016 - 12/2007
8	Membrane Glycoproteins (Membrane Glycoprotein)IBA 01/2019 - 11/2002
7	VaccinesIBA 12/2018 - 04/2004
7	SS1(dsFv)PE38IBA 11/2018 - 11/2002
7	B3(Fv)-PE38KDEL recombinant immunotoxinIBA 01/2018 - 02/2002
7	Paclitaxel (Taxol)FDA LinkGeneric 05/2017 - 08/2006
7	ErbB Receptors (EGF Receptor)IBA 01/2016 - 10/2004
7	Immunoconjugates (Immunoconjugate)IBA 01/2016 - 12/2008
6	Biomarkers (Surrogate Marker)IBA 01/2020 - 04/2012
6	purineIBA 01/2020 - 02/2005
6	TARPIBA 12/2018 - 08/2003
6	Bacterial ToxinsIBA 01/2018 - 02/2010
6	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 01/2017 - 01/2008
6	Neoplasm Antigens (Tumor Antigens)IBA 12/2016 - 04/2004
6	Cytotoxins (Cytolysins)IBA 01/2013 - 07/2002
6	RFB4(dsFv)-PE38 recombinant immunotoxinIBA 10/2011 - 01/2005
5	Pentostatin (Nipent)FDA LinkGeneric 01/2020 - 10/2009
5	Neutralizing AntibodiesIBA 03/2016 - 08/2008
5	epidermal growth factor receptor VIIIIBA 01/2016 - 05/2010
5	Antineoplastic Agents (Antineoplastics)IBA 06/2014 - 01/2006
5	HLA-A2 Antigen (HLA A2 Antigen)IBA 01/2013 - 04/2004
5	Glycoproteins (Glycoprotein)IBA 07/2011 - 06/2002
4	CollagenIBA 01/2021 - 11/2002
4	CreatinineIBA 11/2020 - 05/2012
4	Immune Checkpoint InhibitorsIBA 01/2020 - 12/2016
4	Immunoglobulin FragmentsIBA 01/2020 - 01/2007
4	Cladribine FDA LinkGeneric 01/2020 - 05/2006
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2016 - 06/2011
4	Immunoglobulin G (IgG)IBA 01/2016 - 05/2005
4	Single-Chain AntibodiesIBA 01/2016 - 06/2002
4	Immunoglobulin Variable RegionIBA 11/2014 - 10/2006
4	RNA (Ribonucleic Acid)IBA 05/2008 - 05/2002
3	GlypicansIBA 01/2022 - 05/2017
3	AlbuminsIBA 01/2022 - 10/2018
3	Biological ProductsIBA 03/2020 - 02/2009
3	Rituximab (Mabthera)FDA Link 01/2020 - 07/2002
3	CytokinesIBA 01/2020 - 08/2007
3	Transaminases (Aminotransferases)IBA 10/2017 - 09/2005
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 08/2016 - 04/2004
3	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2016 - 10/2003

Therapy/Procedure

84	Therapeutics 01/2021 - 03/2001
29	Immunotherapy 01/2021 - 03/2002
17	Drug Therapy (Chemotherapy) 01/2020 - 12/2007